Logo image of CAPR

CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

USA - NASDAQ:CAPR - US14070B3096 - Common Stock

7.09 USD
-0.53 (-6.96%)
Last: 10/10/2025, 9:13:54 PM
7 USD
-0.09 (-1.27%)
After Hours: 10/10/2025, 9:13:54 PM
Fundamental Rating

4

Overall CAPR gets a fundamental rating of 4 out of 10. We evaluated CAPR against 536 industry peers in the Biotechnology industry. CAPR has a great financial health rating, but its profitability evaluates not so good. CAPR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CAPR has reported negative net income.
In the past year CAPR has reported a negative cash flow from operations.
CAPR had negative earnings in each of the past 5 years.
In the past 5 years CAPR reported 4 times negative operating cash flow.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

With a Return On Assets value of -52.39%, CAPR perfoms like the industry average, outperforming 48.88% of the companies in the same industry.
Looking at the Return On Equity, with a value of -66.66%, CAPR is in line with its industry, outperforming 58.96% of the companies in the same industry.
Industry RankSector Rank
ROA -52.39%
ROE -66.66%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

7

2. Health

2.1 Basic Checks

CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CAPR has been increased compared to 1 year ago.
CAPR has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CAPR has been reduced compared to a year ago.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 3.33 indicates that CAPR is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.33, CAPR is in the better half of the industry, outperforming 70.52% of the companies in the same industry.
There is no outstanding debt for CAPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.33
ROIC/WACCN/A
WACC9.37%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 4.37 indicates that CAPR has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.37, CAPR is in line with its industry, outperforming 48.32% of the companies in the same industry.
CAPR has a Quick Ratio of 4.37. This indicates that CAPR is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of CAPR (4.37) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.37
Quick Ratio 4.37
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

CAPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -76.34%.
CAPR shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -50.69%.
CAPR shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 85.64% yearly.
EPS 1Y (TTM)-76.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.86%
Revenue 1Y (TTM)-50.69%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%

3.2 Future

CAPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.40% yearly.
CAPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.86% yearly.
EPS Next Y-85.41%
EPS Next 2Y-23.76%
EPS Next 3Y20.05%
EPS Next 5Y27.4%
Revenue Next Year-92.12%
Revenue Next 2Y151.01%
Revenue Next 3Y86.61%
Revenue Next 5Y75.86%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -5 -10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CAPR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CAPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

A more expensive valuation may be justified as CAPR's earnings are expected to grow with 20.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-23.76%
EPS Next 3Y20.05%

More info and screens

0

5. Dividend

5.1 Amount

CAPR does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (10/10/2025, 9:13:54 PM)

After market: 7 -0.09 (-1.27%)

7.09

-0.53 (-6.96%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11/amc
Earnings (Next)11-11 2025-11-11
Inst Owners30.53%
Inst Owner Change0.23%
Ins Owners1.16%
Ins Owner Change0%
Market Cap324.15M
Analysts83.75
Price Target21.01 (196.33%)
Short Float %31.93%
Short Ratio7.64
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-41.63%
Min EPS beat(2)-64.08%
Max EPS beat(2)-19.18%
EPS beat(4)1
Avg EPS beat(4)-11.7%
Min EPS beat(4)-64.08%
Max EPS beat(4)40.43%
EPS beat(8)4
Avg EPS beat(8)-14.71%
EPS beat(12)8
Avg EPS beat(12)-5.96%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-36.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)92.08%
Revenue beat(8)4
Avg Revenue beat(8)-10.81%
Revenue beat(12)8
Avg Revenue beat(12)1660.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-51.1%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2185.71%
EPS NY rev (1m)-2.05%
EPS NY rev (3m)-129.6%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-98.65%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-98.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 24.2
P/FCF N/A
P/OCF N/A
P/B 3.09
P/tB 3.09
EV/EBITDA N/A
EPS(TTM)-1.64
EYN/A
EPS(NY)-1.84
Fwd EYN/A
FCF(TTM)-1.23
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.29
BVpS2.3
TBVpS2.3
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -52.39%
ROE -66.66%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 207.77%
Cap/Sales 25.27%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.37
Quick Ratio 4.37
Altman-Z 3.33
F-Score4
WACC9.37%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-76.34%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-62.86%
EPS Next Y-85.41%
EPS Next 2Y-23.76%
EPS Next 3Y20.05%
EPS Next 5Y27.4%
Revenue 1Y (TTM)-50.69%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%
Revenue Next Year-92.12%
Revenue Next 2Y151.01%
Revenue Next 3Y86.61%
Revenue Next 5Y75.86%
EBIT growth 1Y-144.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-132.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-171.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-197.89%
OCF growth 3YN/A
OCF growth 5YN/A